Genmab A/S To Receive Milestone Payment In Duobody Platform Collaboration With Janssen Biotech Inc. – Financial Guidance Improved

Copenhagen, Denmark; December 6, 2013 – Genmab A/S (OMX: GEN) announced today it has reached a new milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. (“Janssen”), triggering a $4 million milestone. The milestone payment is for pre-clinical progress on the EM1-mAb DuoBody product which targets EGFr and cMet, two validated targets for cancer therapy.

Help employers find you! Check out all the jobs and post your resume.